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Background: Biomarkers for the early prediction of canine acute kidney injury (AKI) are clinically important.
Recently, neutrophil gelatinase-associated lipocalin (NGAL) was found to be a sensitive biomarker for the prediction
of human AKI at a very early stage and the development of AKI after surgery. However, NGAL has not yet been
studied with respect to dog kidney diseases. The application of NGAL canine AKI was investigated in this study.
Results: The canine NGAL gene was successfully cloned and expressed. Polyclonal antibodies against canine NGAL
were generated and used to develop an ELISA for measuring NGAL protein in serum and urine samples that were
collected from 39 dogs at different time points after surgery.
AKI was defined by the standard method, namely a serum creatinine increase of greater than or equal to
26.5 μmol/L from baseline within 48 h. At 12 h after surgery, compared to the group without AKI (12 dogs), the
NGAL level in the urine of seven dogs with AKI was significantly increased (median 178.4 pg/mL vs. 88.0 pg/mL),
and this difference was sustained to 72 h.
Conclusion: As the increase in NGAL occurred much earlier than the increase in serum creatinine, urine NGAL
seems to be able to serve as a sensitive and specific biomarker for the prediction of AKI in dogs.
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Acute kidney injury (AKI) shows high mortality and
occurs in patients undergoing both cardiac or non-
cardiac surgery [1], and among those in an intensive care
unit (ICU). However, due to the lack of a consensus def-
inition of AKI severity, the early recognition of AKI has
been difficult. In the past, the Acute Dialysis Quality Ini-
tiative (ADQI) group published RIFLE criteria in which
the severity of AKI was graded into Risk, Injury and Fail-
ure based on changes in serum creatinine and urine out-
put; using this approach chronic renal failure was
classified into the Loss and End stage [2]. More recently,
the Acute Kidney Injury Network (AKIN) modified these
criteria to increase the sensitivity, and recommended* Correspondence: wlhsu@dragon.nchu.edu.tw
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reproduction in any medium, provided the orthat a small change in serum creatinine (more than
26.5 μmol/L from baseline) within 48 h be recognized as
stage I AKI [3]. Despite the lack of gold standard criteria
for AKI in veterinary medicine, the application of the
human criteria has been verified as applicable to dogs
with AKI [4,5].
Based on the consensus definition, the prediction of
AKI has been improved. At present, AKI is mainly diag-
nosed based on an elevation in serum creatinine; how-
ever, serum creatinine can be affected by age, gender,
muscle mass, and hydration status; furthermore, it only
rises after a loss of renal function greater than 50% [2].
In addition, the increase in serum creatinine cannot be a
real time indicator of renal injury since days are needed
to reach a steady state between the production of serum
creatinine and the decrease in excretion of serum cre-
atinine [6,7]. As AKI is important not only in humans. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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can be used to indicate AKI at early state are needed.
Neutrophil gelatinase-associated lipocalin (NGAL, also
called lipocalin 2 or 24p3), a small 25 kDa protein that
belongs to lopocalin family, is highly expressed during
ischemic renal injury in animal models [8]. Very recently,
a number of studies have indicated that serum and urine
NGAL are sensitive and specific biomarkers for the pre-
diction of AKI [9-11] as well as the development of AKI
among human patients after an operation, such as cardiac
surgery [12-15], non-cardiac surgery [16], renal trans-
plantation [17,18], and among trauma patients [19], as
well as when there is IgA nephropathy [20].
Nevertheless, the role of NGAL in dogs has never
been studied. Therefore the aim of the present study
was to determine whether NGAL can be used for the
early prediction of AKI in dogs. In this work, we first
established an ELISA that allows the measurement of ca-
nine NGAL. Additionally, the validity of serum NGAL
and urine NGAL for the early identification of AKI in
post surgery dogs was determined.Methods
Amplification of NGAL cDNA
Mammary gland tumors (MGT) have been reported to
highly express NGAL [21] and therefore, in order to
clone the NGAL gene sequence, total RNA was
extracted from MGT by reagent TRIzol (Invitrogen)
according to the manufacturer’s instructions. The first-
strand cDNA was synthesized by SuperScript III reverse
transcriptase (Invitrogen) using RNA (1 μg) and primers
(50 μM). Subsequently, NGAL was amplified by poly-
merase chain reaction (PCR) with primer designed
according to GenBank accession no. XM_548441 (NGAL-
F: 50-ATGACCCAAGTTCTCCTGTG; NGAL-R: 50-
TCACTCATCAATGCACTGGTC). The thermocycling
conditions started with 94°C for 5 min followed by 35 cycles
of heat denaturation at 94°C for 30 s, primer annealing at
60°C for 30 s, DNA extension at 72°C for 30 s and a final
extension at 72°C for 5 min. The resulting PCR product
with predicted size was isolated and cloned into PCR 2.1
TOPO vector (Invitrogen), designated c-NGAL/TOPO.
The identity of the NGAL was verified by automated
sequencing (Mission Biotech, Taipei, Taiwan).Construction of a plasmid expressing recombinant NGAL
Initially, the canine NGAL gene was amplified by PCR
from the c-NGAL/TOPO plasmid using the primer set F-
BamH: 5'-aggatccaatgacccaagttctcctg-3' and R- Xho: 5’-
ttctcgagctcatcaatgcactggtc-3‘. The PCR conditions were
similar to that used for NGAL amplification from tissue,
except for primer annealing at 49°C. Subsequently, the
PCR product was digested with BamH I/Xho I and clonedinto pET32b. The resulting plasmid was confirmed by
bi-directional sequencing.
Preparation of recombinant dog NGAL
Protein expression was carried out in E. coli. strain BL21
AI (Invitrogen) following the procedures described pre-
viously [22]. Briefly, protein expression was induced with
isopropyl-β-D-1-thiogalactopyranoside (IPTG, 0.8 mM)
and 0.2% L-arabinose (CALBIOCHEM) at 16°C for 24 h.
The bacteria pellets were resuspended in lysis buffer
(500 mM NaCl, 500 mM Tris–HCl, 20 mM imidazole,
and 8 M urea; pH 7.4) and this was followed by
three sonication cycles of 30 sec each (550 Sonic
Dismembrator; Fisher Scientific). After a second
centrifugation, the cell supernatant containing the recom-
binant proteins was recovered and purified using chelating
Sepharose Fast Flow (GE Healthcare) by following the
manufacturer’s instructions. Finally, the bound protein
was eluted in 4 mL elution buffer (0.05 M Tris–HCl,
0.5 M NaCl, 400 mM imidazole, and 8 M urea, pH 7.4)
and then dialyzed against 1x PBS at 4°C to remove excess
imidazole and urea.
Western blotting
Purified proteins were separated by 12% sodium dodecyl
sulfate polyacrylamide gel electrophoresis (SDS-PAGE)
and then electrophoretically transferred to nitrocellulose
membrane. The procedures for Western blot analysis
followed those in a previous report [23]. Briefly, after a
blocking step in PBS containing 0.1% Tween-20 (PBST)
and 5% fat-free dried milk for 1 h at room temperature,
the membranes were incubated with 1:5000 diluted
anti-His tag antibody (AbD Serotec) or 1:500 diluted
rabbit immunized with recombinant NGAL in PBST-5%
dried milk at 4°C for overnight. Next, the filter was
washed in PBST, which was followed by incubation
with horseradish peroxidase (HRP)-conjugated secondary
antibody in PBST-2% dried milk at room temperature for
1 h. After extensive washing with PBST, the filter was
developed using an enzyme-linked chemiluminescence
system (ECL, Amersham, GE Healthcare) and exposed
to X-ray film.
Production of antibodies against NGAL
Three BALB/c mice, aged eight weeks and three-month
old New Zealand white rabbits were immunized with
50 μg NGAL/mouse (200 μg/rabbit) mixed with complete
Freund's adjuvant (Sigma). After initial immunization, two
boosters of the same dose were given at two-week interval.
Blood was collected from the mouse submandibular vein
by a lancet and from the ear vein of the rabbits. After cen-
trifugation, the plasma was transferred to a new tube and
stored at -20°C until use. The study was approved by the
Institutional Animal Care and Use Committee of National
Lee et al. BMC Veterinary Research 2012, 8:248 Page 3 of 9
http://www.biomedcentral.com/1746-6148/8/248University of Chung-Hsing University, permit number:
100-66.
Establishment of a sandwich ELISA for the detection of
canine NGAL
Our NGAL ELISA was optimized as follows. A checker-
board titration was initially conducted using various
concentrations of the recombinant canine NGAL protein
(at concentrations of 0, 2.48, 7.4, 22.3, 67, 200, and
600 pg/mL) in combination with serially diluted rabbit
serum (dilutions of 1:100, 1:200, 1:400, 1:800, 1:1600,
and 1:3200). All combinations were repeated in tripli-
cate. It was found that the 1: 800 dilution of rabbit
serum was sufficient to give strong signal with the lower
concentration of NGAL proteins and, based on this,
1:800 diluted rabbit serum was used as the capture anti-
body in our Sandwich ELISA. The dilution of the mouse
serum, as the detector antibody, was optimized following
the same strategy.
After optimization, the ELISA conditions were used to
detect NGAL in clinical samples. To do this, a 96-well
microplate was coated with 100 μL of rabbit sera con-
taining anti-NGAL polyclonal antibody (the capture
antibody) at 1:800 dilution in coating buffer (0.15 M
sodium carbonate, 0.35 M sodium bicarbonate, pH 9.6)
at 37°C for 1 h. After blocking, the test samples (20-fold
diluted with PBS-T containing 5% dried milk), recombin-
ant NGAL protein at known concentrations as positive
controls, and calibrator (diluted with blocking buffer)
were individually added to each well and incubated at 4°C
overnight. After washing with PBS-T, each well received
100 μL of mouse anti-NGAL polyclonal antibody
(detector antibody, 1:3000 diluted in PBS-T containing 5%
fat-free dried milk). After incubation at 37°C for 1 h, HRP
conjugated goat anti-mouse IgG antibody (5,000 fold
diluted in blocking buffer) was added to the wells. After
1 h incubation, the result was visualized using tetra-
methylbenzidine (TMB) substrate kit (Clinical Science
Laboratory, Inc.). The optical density (OD) of each
well was read at 450 nm using a microplate reader
(TECAN). Each sample was analyzed in triplicate, and
the OD of the triplicates was averaged. Samples with
an OD value three times greater than the negative
control serum were considered positive. A commercial
Dog NGAL ELISA kit (BioPorto Diagnostics, kit 043)
was compared with our results to assess the performance
of our sandwich ELISA. Linear regression was conducted
to measure the correlation between the commercial
ELISA kit and our sandwich ELISA.
Cases and sample collection
In this study, cases that had undergone surgery at the
Veterinary Teaching Hospital, National Chung Hsing
University, between 2009 and 2011 were enrolled. Toobviate postoperative volume depletion and to avoid
prerenal azotemia, all dogs received fluid transfusion for
maintenance during and after surgery. Prior to the
surgery, blood and urine samples were collected, while
clinico-pathological information was simultaneously
recorded. In addition, demographic information, including
age, sex, body weight, and surgery type of each case, was
also recorded. The anesthesia protocol was individually
set for each patient. Generally, the preanesthetic agents,
including opioid, midazolam/ketamine and propofol, were
used for induction and isoflurane was administrated for
general anesthesia. Serum and urine samples were
obtained for NGAL analysis before the surgery and at
frequent intervals after surgery when this was possible
(12 h, 24 h, 48 h and 72 h post operation). The urine and
serum supernatants were stored at -80°C until the NGAL
test was conducted. For comparison, serum creatinine was
simultaneously tested at the same time points.Data categories
Dogs with an elevated serum creatinine (> 132.6 μmol/L)
or relevant renal clinical signs/history such as polyuria,
polydipsia, oliguria, changes in the size of the kidneys,
weight loss, obstructive urinary disease and proteinuria
before surgery were excluded from the AKI study. The
remaining animals were included in the study, enrolled for
urine NGAL detection and used to compare the data from
the in-house ELISA and commercial ELISA. Corre-
sponding to the AKIN criteria [3], the serum creatinine of
each case was taken as the baseline. The cases with a
serum creatinine level that became raised to 26.5 μmol/L
or more from the baseline within 48 h were considered to
form the postoperative ‘AKI group’. The remaining cases
formed the ‘No AKI group’. In addition, the operation
duration and the use of any nephrotoxic related medicine
including non-steroidal anti-inflammatory drugs (NSAIDs),
angiotension-convertion enzyme inhibitors (ACE-inhibi-
tors) and chemotherapeutic medicines such as carboplatin
were also recorded.Statistical methods
SPSS 16.0 was used for analysis. For continuous variables,
normally distributed variables are represented as a mean ±
S.E.M and were compared by the independent Student’s
t test or by one way ANOVA coupled with post hoc
analysis by the Tukey’s method. Non-normal distribution
variables were compared by the Mann–Whitney U test
and recorded as medians (interquartile range, IQR). The
χ2 test or Fisher’s exact test were used for categorical
variable comparison. Univariate analysis of the serum and
urine NGAL values by logistic regression was applied to
identify the variables that were possible associated with
AKI in dogs post operation.
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Preparation and verification of the NGAL antibodies
To develop an in-house NGAL ELSIA, the entire coding
region (597 nucleotides; 199 amino acids) of the canine
NGAL gene was cloned into the expression vector
pET32a (Figure 1A) and the recombinant NGAL protein
was expressed and identified. As shown in Figure 1B, the
thioredoxine-NGAL was successfully expressed with an
expected molecular weight of approximately 42 kDa
(Figure 1B). The identity of the NGAL protein was
confirmed by Western blot analysis using antibody
against the histidine tag (Figure 1C) and by mass
spectrometry (data not shown).
As analyzed by Western blotting, the sera from the
mice and rabbits immunized with NGAL were able to
recognize the recombinant NGAL protein (Figure 2A,
sample 2, 4) and also specifically detected canine NGAL
(25 kDa) from two renal failure dogs in which the
presence of NGAL had been diagnosed by a commercial kit
(Figure 2B, sample 2 and 3). This confirms the specificity
of antibodies produced by the present study.
Establishing the ELISA for NGAL detection
Based on the checkerboard titration result, the condi-
tion of ELISA for the detection of canine NGAL was
optimized as 1:3000 diluted mouse serum and 1:800
diluted rabbit serum, which were used as the detector
antibody and the capture antibody, respectively.
Following optimization, twenty clinic urine samples
collected from 10 healthy dogs and 10 renal failure
dogs were analyzed. To evaluate the performance of
the in-house NGAL ELISA, these samples at a dilu-
tion of 1:20 were also tested by a commercial NGAL
kit in parallel. Results of commercial kit indicated
that the OD of the urine samples from healthy dogs
ranged from 0.042 - 0.521 (equivalent to 0.93 pg/mL -Figure 1 Cloning and expression of the recombinant canine NGAL pr
NGAL construct is shown. The open reading frame of the canine NGAL wa
and linked to six histines. The size of recombinant canine NGAL protein wa
induced by IPTG in the host bacteria E. coli. As indicated by the arrowhead
expressed (lane 2) and purified using Ni-NTA chromatography (lane 3). The
identified by Western blotting using an antibody against the His tag (C). M159.6 pg/mL of calibrator NGAL protein), and that
higher readings (0.384 - 2.396; 111.5 pg/mL - 785.6 pg/mL
of the calibrator NGAL protein) were detected from
renal failure dogs (Figure 3A, left panel). Consistent
results were obtained using our NGAL ELISA with a
higher OD being detected from the renal failure dogs
(0.306 - 1.507; 306 pg/mL - 4492 pg/mL of recombinant
NGAL protein) compared to the healthy group
(0.114 - 0.356; 0 pg/mL - 314.3 pg/mL of recombinant
NGAL protein; Figure 3A, right panel).
Comparison of two ELISA methods
As the format, signal detection system, and assay
standardization of these two ELISA systems were differ-
ent in many ways. Bland-Altman plot for twenty urine
samples was first performed to assess the agreement of
the two methods. The mean difference between our
ELISA and the commercial one is 1064.2 pg/mL, and
95% limits of agreement are -1739.4 pg/mL and
3867.8 pg/mL (Figure 3B). Linear regression and coeffi-
cient of correlation analyses were used to correlate the
results of these two ELISA systems. A cross-sectional
pilot study was designed to verify the standardized
commercial ELISA kit against our NGAL ELISA
assay. As shown in Figure 3C, NGAL concentrations
in 21 urine samples and 8 calibration standards
(NGAL range, 0 to 400 pg/mL) were determined by
the two assays and these were found to be highly
correlated (r = 0.96).
The equation obtained was Y = 0.1771X + 131.1735
with a coefficient of correlation 0.9646 and a r2 = 0.9307
(p < 0.0001); this was then used to correlate the concen-
tration of canine NGAL determined by our ELISA assay
using the purified recombinant fusion NGAL protein as
calibrators with that obtained by the commercial ELISA
kit using the standard calibrator NGAL protein.otein used to raise the antibodies. (A) A schematic illustration of the
s inserted into the vector pET32 downstream of the thioredoxin gene
s approximately 42 kDa. (B) The expression of canine NGAL was
, recombinant NGAL, with a predicted size of approximate 42 kDa, was
identity of the recombinant NGAL protein (lane 2) was initially
: protein size markers, lane 1: non-induction cell lysate.
Figure 2 Examination of the specificity of the two polyclonal antibodies against canine NGAL by Western blotting. (A) The recombinant
NGAL protein was separated by SDS-PAGE and processed for Western blot analysis. As indicated by the arrowhead, the positive control antibody
(+; antibody against histidine) as well as the sera of the mice (lane 2) and the rabbit (lane 4) immunized with NGAL were able to recognize the
recombinant canine NGAL protein (~42 kDa), but the pre-immunized sera of mouse (lane 1) and rabbit (lane 3) failed to detect recombinant
NGAL protein. (B) Three clinic urine samples collected from one healthy dog (lane 1) and two renal failure dogs (lane 2 and 3) were used to
examine the specificity of serum obtained from mice and rabbits immunized with recombinant NGAL. Both rabbit and mouse sera were able to
recognize the endogenous NGAL (~25 kDa) as indicated by the arrowheads.
Figure 3 A comparison of the results obtained by a commercial ELISA kit and by our NGAL ELISA. (A) The urine NGAL(uNGAL)
concentrations of twenty urine samples collected from 10 healthy and 10 renal failure dogs measured by Commercial ELISA kit (left panel) and by
our ELISA (right panel). (B) Bland-Altman plot of uNGAL concentrations from 20 urine samples measured by the two methods. (C) Linear
regression analysis and coefficient of correlation analysis (Software SigmaPlot 10.0) were conducted to correlate the results of these two ELISA
systems. Each column represents the μNGAL concentration of a dog.
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after surgery using NGAL ELISA
Next, our ELISA was used to analyze the level of NGAL
in dogs that had undergone surgery. Of the 39 cases
investigated, 13 were for orthopedic surgery, 20 were for
soft tissue surgery and six were for tumor mass removal.
An increase in serum creatinine greater or equal to
26.5 μmol/L within 48 h post surgery was found to have
occurred in 12 cases (30.7%), which were then classified
into the AKI group. The remaining dogs were classified
into the No AKI group.
The two groups were not significant different in
terms of age, gender and body weight. Neither was
any significant differences noted for BUN and serum
creatinine between the AKI and No AKI groups prior
to the surgery. However, the surgery duration of the
AKI group (3.0 ± 0.8 h) was longer than that of the No
AKI group (1.4 ± 0.1 h) and this p-value (0.05) almost
reached significance (Table 1).
The median urine NGAL concentrations at baseline
and at different time points after surgery for each dog
from the two groups are shown in Table 2. Compared
with the No AKI group, the median concentration of
urine NGAL in the AKI group rose significantly at 12 h
(median 178.4 pg/mL vs. 88.0 pg/mL), and was also
found to be higher at 24 h (median 243.6 pg/mL vs.
128.2 pg/mL p = 0.059), 48 h (median 201.7 pg/mL vs.
155 pg/mL p = 0.035), and 72 h (276.1 pg/mL vs. 70 pg/mL
p = 0.056) (Table 2). Thus the increase in NGAL was
sustained for at least three days post surgery.
In contrast, when the serum creatinine levels were
examined, no distinct difference was found between the
two groups of dogs until 24 h post surgery (Table 2).
However, when the NGAL concentrations in the serum
of the AKI and No AKI groups at the various times were
compared, they were found not to be significant
different between the two groups (Table 2). In addition,
there was no significant difference between the AKI and
No AKI groups for BUN.Table 1 Demographic information, laboratory information pr
non AKI groups
Parameter AKI
Age (years) 3.7 ± 0.8, n = 12
Bodyweight (kg) 10.0 ± 2.0, n = 12
Admission BUN (mmol/L) 6.0 ± 0.85, n = 12
Surgery duration (h) 3.0 ± 0.8, n = 12
Admission Creatinine (μmol/L) 88.4 (53.0), n = 12
Gender (female) 58.3% (7/12)
Nephrotoxic drugs used b 50.0% (6/12)
Continuous data agreeing with a normal distribution are presented as means ± S.E.M
a percentage.
ap < 0.05 indicates a significant difference.
bNephrotoxic drugs used include NSAIDs, aminoglycoside antibiotics, ACE-inhibitorsUsing logistic regression, it was found that the urine
NGAL at 12 h and 48 h significantly increased the odds
ratio for AKI. However, an increased duration of surgery
also increased the odds ratio for AKI with the possibility
of AKI being increased as surgery is prolonged (Table 3).
Discussion
In the present study, we established an antigen capture
ELISA for measuring urine NGAL in dogs. Using this
platform, urine NGAL was shown to act as an early
predictive biomarker for acute kidney injury (AKI) after
surgery. Recently, several studies have proposed that
NGAL ought to be able to serve as a novel biomarker for
predicting renal failure in humans [11,13,14]. However, up
to the present, measurement of urine NGAL levels has
not yet been included as a routine diagnosis for the pre-
diction of renal function. Moreover, studies targeting
NGAL in dogs have not been reported up to the present
and as a result one might expect the detection reagent/kit
to have limited availability. To be able to monitor NGAL
levels in many individuals, it is important to develop
a reliable and cost effective detection system.
The detection and measurement of NGAL level can be
achieved by a range of methods including Western blot
analysis and ELISA. So far, antibodies specific for canine
NGAL are not commercially available; most of the com-
mercial NGAL antibodies in use are specific for the
human protein and cross reactivity with canine NGAL
has been suggested based on gene homology and se-
quence similarity. Although a canine NGAL ELISA assay
kit is commercially available, it is very expensive. In this
context, the production of an antibody against canine
NGAL is useful when developing ELISA and other
assays for measuring NGAL levels in dogs. In current
study, we have identified and expressed recombinant
canine NGAL and used this protein to generate two dif-
ferent polyclonal antibodies. Compared with the results
obtained from the commercial NGAL ELISA kit, we
noticed that the overall NGAL concentrations of testedior to the surgery and surgery duration in the AKI and
No AKI Pa
4.1 ± 0.7, n = 26 0.749
14 ± 2.4, n = 27 0.173
6.28 ± 0.43, n = 27 0.76
1.4 ± 0.1, n = 26 0.05
88.4 (26.5), n = 27 0.208
70.4% (19/27) 0.486
40.7% (11/27) 0.590
., otherwise, the median (IQR) are presented; categorical data are reported as
and chemotherapeutic medicine such as carboplatin.
Table 2 Median/mean of urine and serum NGAL levels as well as serum creatinine levels at various time points
Time point AKI No AKI pa
Urine NGAL (pg/mL)
0 h 51.4 (52.1), n = 11 83.9 (216.3), n = 25 0.959
12 h 178.4 (240.3), n = 7 88.0 (195.2), n = 12 0.022
24 h 243.6 (170.3), n = 10 128.2 (218.5), n = 24 0.059
48 h 201.7 (256.6), n = 11 155.7 (261.8), n = 25 0.035
72 h 276.1(269.6), n = 10 70.0 (257.2), n = 17 0.056
Max after 72 h 297.5 (193.9), n = 11 161.1 (199.3), n = 25 0.041
Serum NGAL (pg/mL)
0 h 254.6 ± 35.5, n = 8 217.9 ± 22.0, n = 16 0.368
12 h 177.5 ± 33.8, n = 7 209.4 ± 27.0 n = 13 0.481
24 h 226.8 ± 28.9, n = 12 230.9 ± 21.1, n = 25 0.910
48 h 269.3 ± 31.1, n = 12 228.3 ± 23.4, n = 25 0.313
72 h 254.5 ± 38.1, n = 9 217.5 ± 22.0, n = 18 0.377
Max after 72 h 297.5 ± 29.2, n = 12 254.9 ± 22.4, n = 26 0.277
Serum Creatinine (μmol/L)
0 h 79.6 ± 7.1, n = 12 88.4 ± 3.5, n = 27 0.203
12 h 77.8 ± 11.5, n = 6 83.1 ± 3.5, n = 13 0.583
24 h 104.3 ± 8.8, n = 12 85.7 ± 2.7, n = 26 0.040
48 h 103.4 ± 0.1, n = 12 86.6 ± 2.7, n = 26 0.027
72 h 113.2 ± 8.8, n = 10 85.7 ± 2.9, n = 21 0.005
Mean ± S.E.M. and median (IQR) are used to present normally and non-normally distributed continuous data, respectively.
ap < 0.05 indicates a significant difference.
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used. The difference observed between these assays is prob-
ably, to a large degree, due to differences in the ELISA for-
mat, to higher antibody affinity, to better amplification of
the detection signal, and to improved assay standardization.
Nevertheless, the linear regression analysis indicated that
results of in-house ELISA are highly correlated with the
commercial kit, and that the NGAL concentration can be
converted between these two systems using an equation.
Hence, our in-house ELISA has the potential to be a useful
tool when studying NGAL in dogs.
To our knowledge, this is the first study to investigate
the role of NGAL in dogs with renal disease. Results of
this study indicate that, as with humans, an increase in
urine NGAL concentration is able to predict kidney
injury in dogs after surgery. Compared with using serum
creatinine for the diagnosis of AKI at 48 h post surgery,Table 3 Results of the univariate analysis to identify
variables significantly associated with AKI (P < 0.05) in
this study
Variables Odds ratio 95% Confidence interval
Urine NGAL 12 h 1.013 1.001–1.025
Urine NGAL 48 h 1.007 1.001–1.013
Surgery duration (h) 1.969 1.018–3.811an increase in urine NGAL from the baseline is able to
pinpoint AKI as early as 12 h after surgery in dogs.
Noticeably, the 2 h urine NGAL level has been found
to be an effective biomarker for the prediction of AKI in
several human medical studies [12-14]. In our study, the
best time point for classifying dogs into those with and
without AKI was much later at 12 h post surgery. As
urinary catheterization of each dog after surgery cannot
be accomplished, the collection of urine from dogs at 2 h
post surgery is not routinely possible; therefore we may
have missed the earliest point at which urine NGAL is
elevated. Furthermore, due to limited clinical accessibility,
urine could not be obtained from all the dogs at all time
points and this resulted in missing data, which reduced
the statistical power of our study. However, this pre-
liminary study still clearly shows that urine NGAL level is
able to act as a much earlier biomarker than serum
creatinine when detecting post surgery AKI in dogs.
Nonetheless, more research is needed to validate NGAL
levels as a biomarker in dogs with various renal diseases
and in dogs at different stages of disease progression.
Unlike previous human medical studies [12-14], serum
NGAL was not as sensitive as urine NGAL in dogs. The
reasons for this may involve the expression of NGAL
occurring not only in the renal tubules but also in the
respiratory tract, stomach and colon; furthermore, NGAL
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tissue injury [6]. Thus NGAL accumulates separately in
two pools, namely a systemic and a renal pool [24]. During
AKI, serum NGAL may also be derived from injured tissues
other than the kidneys; these will both contribute to the
systemic pool. Hence, serum NGAL concentration is not in
these circumstances a specific indicator of disease with a
renal origin. Additionally, studies of NGAL in human AKI
have involved specific types of major surgery such as
cardiac surgery [6]; however, in our study the types of
surgery that the dogs underwent were diverse. The diver-
sity of the surgery may help to obscure the serum NGAL
results compared to the urine NGAL results. In contrast
to serum NGAL, an increase in urine NGAL only occurs
when the renal absorption ability of NGAL is disturbed by
the kidney damage [25].
Despite the fact that development of post-operative
AKI occurs most often after cardiac surgery in humans,
it also occurs after human non-cardiac surgery [1,26].
Although the mechanism of post-surgery AKI is well
understood, some risk factors such as age, emergency
status, high risk surgery, ischemic heart disease [1], liver
disease, body mass index and chronic obstructive
pulmonary disease have been reported to predispose
patients to suffer renal insult after surgery [26]. In the
veterinary field, post-surgery AKI in dogs has been rarely
reported, but this may be due to the lack of the early
biomarker and a consensus standard. In our study, based
on the AKIN criteria and the elevation of urine NGAL,
AKI in dogs can now be recognized as early as 12 h
post surgery.
The use of nephrotoxic medicines might have interfered
with the results of this study [27]. Nevertheless, we found
that the percentage of patients using nephrotoxic medi-
cine in the AKI group was not significantly higher than in
No AKI groups and thus it would seem that this variable
can be neglected as an influence on our results.
Several criteria have been established to increase the sen-
sitivity of AKI detection at the early stage; however, these
criteria are based on the loss of renal function. As an
applicable tool for testing renal function, serum creatinine
was used as the standard for AKI. However, unlike serum
creatinine, urine NGAL is a real-time indicator of active
kidney damage in humans [28] and can be used to examine
the progressive kidney disease. Theoretically, the use of
serum creatinine levels which was a renal functional mar-
ker, even with new criteria, cannot exclude AKI. However,
before a more reliable standard is established, serum
creatinine is the only alternative. In this study, the elevation
of NGAL was found to be a suitable biomarker that is able
to detect at an earlier time point than serum creatinine in
dogs with postoperative AKI. The results indicated that,
like in humans, urine NGAL can be applied as a useful
biomarker for the detection of AKI in dogs. However,further studies are needed in order to understand the role
of NGAL in various different kidney diseases.
Conclusions
For the first time in this study, an antigen capture ELISA
was successfully established that allows the detection and
quantification of canine NGAL. Urine NGAL was found
to be a sensitive biomarker for AKI in dogs. In terms of
the time of appearance of the two biomarkers that can be
used to detect AKI, the increase in urine NGAL occurs
much earlier than the increase in serum creatinine.
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